Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 141

1.

Validation of tumour models for use in anticancer nanomedicine evaluation: the EPR effect and cathepsin B-mediated drug release rate.

Duncan R, Sat-Klopsch YN, Burger AM, Bibby MC, Fiebig HH, Sausville EA.

Cancer Chemother Pharmacol. 2013 Aug;72(2):417-27.

2.

Use of the hollow fiber assay for the evaluation of DNA damaging agents.

Veiga JP, Cooper PA, Pors K, Patterson LH, Bibby MC, Shnyder SD.

J Pharmacol Toxicol Methods. 2011 Nov-Dec;64(3):226-32. doi: 10.1016/j.vascn.2011.04.006. Epub 2011 Apr 30.

PMID:
21569858
3.

Potentiation of the activity of cisplatin in a human colon tumour xenograft model by auristatin PYE, a structural modification of dolastatin 10.

Prokopiou EM, Cooper PA, Pettit GR, Bibby MC, Shnyder SD.

Mol Med Rep. 2010 Mar-Apr;3(2):309-13. doi: 10.3892/mmr_00000256.

PMID:
21472238
4.

Development of a novel tumor-targeted vascular disrupting agent activated by membrane-type matrix metalloproteinases.

Atkinson JM, Falconer RA, Edwards DR, Pennington CJ, Siller CS, Shnyder SD, Bibby MC, Patterson LH, Loadman PM, Gill JH.

Cancer Res. 2010 Sep 1;70(17):6902-12. doi: 10.1158/0008-5472.CAN-10-1440. Epub 2010 Jul 27.

5.

Sodium pancratistatin 3,4-o-cyclic phosphate, a water-soluble synthetic derivative of pancratistatin, is highly effective in a human colon tumor model.

Shnyder SD, Cooper PA, Millington NJ, Gill JH, Bibby MC.

J Nat Prod. 2008 Mar;71(3):321-4. Epub 2007 Dec 22.

PMID:
18154271
6.

Auristatin PYE, a novel synthetic derivative of dolastatin 10, is highly effective in human colon tumour models.

Shnyder SD, Cooper PA, Millington NJ, Pettit GR, Bibby MC.

Int J Oncol. 2007 Aug;31(2):353-60.

PMID:
17611692
7.

Preclinical pharmacology of the pyrrolobenzodiazepine (PBD) monomer DRH-417 (NSC 709119).

Burger AM, Loadman PM, Thurston DE, Schultz R, Fiebig HH, Bibby MC.

J Chemother. 2007 Feb;19(1):66-78.

PMID:
17309854
8.

The hollow fibre model--facilitating anti-cancer pre-clinical pharmacodynamics and improving animal welfare.

Suggitt M, Cooper PA, Shnyder SD, Bibby MC.

Int J Oncol. 2006 Dec;29(6):1493-9.

PMID:
17088988
9.

The hollow fiber assay for drug responsiveness in the Ewing's sarcoma family of tumors.

Bridges EM, Bibby MC, Burchill SA.

J Pediatr. 2006 Jul;149(1):103-11.

PMID:
16860137
10.

Reducing the cost of screening novel agents using the hollow fibre assay.

Shnyder SD, Cooper PA, Scally AJ, Bibby MC.

Anticancer Res. 2006 May-Jun;26(3A):2049-52.

11.

Polar, functionalized guanine-O6 derivatives resistant to repair by O6-alkylguanine-DNA alkyltransferase: implications for the design of DNA-modifying drugs.

Pletsas D, Wheelhouse RT, Pletsa V, Nicolaou A, Jenkins TC, Bibby MC, Kyrtopoulos SA.

Eur J Med Chem. 2006 Mar;41(3):330-9. Epub 2006 Feb 3.

PMID:
16458393
12.

Antineoplastic agents. 509: synthesis of fluorcombstatin phosphate and related 3-halostilbenes(1).

Pettit GR, Minardi MD, Rosenberg HJ, Hamel E, Bibby MC, Martin SW, Jung MK, Pettit RK, Cuthbertson TJ, Chapuis JC.

J Nat Prod. 2005 Oct;68(10):1450-8.

PMID:
16252907
13.

Development of a modified hollow fibre assay for studying agents targeting the tumour neovasculature.

Shnyder SD, Hasan J, Cooper PA, Pilarinou E, Jubb E, Jayson GC, Bibby MC.

Anticancer Res. 2005 May-Jun;25(3B):1889-94.

14.

Expression of HIF-1alpha and Glut-1 in human bladder cancer.

Palit V, Phillips RM, Puri R, Shah T, Bibby MC.

Oncol Rep. 2005 Oct;14(4):909-13.

PMID:
16142350
15.

Expression of matrix metalloproteinase-10 in human bladder transitional cell carcinoma.

Seargent JM, Loadman PM, Martin SW, Naylor B, Bibby MC, Gill JH.

Urology. 2005 Apr;65(4):815-20.

PMID:
15833553
16.

MMP-10 is overexpressed, proteolytically active, and a potential target for therapeutic intervention in human lung carcinomas.

Gill JH, Kirwan IG, Seargent JM, Martin SW, Tijani S, Anikin VA, Mearns AJ, Bibby MC, Anthoney A, Loadman PM.

Neoplasia. 2004 Nov-Dec;6(6):777-85.

17.

50 years of preclinical anticancer drug screening: empirical to target-driven approaches.

Suggitt M, Bibby MC.

Clin Cancer Res. 2005 Feb 1;11(3):971-81. Review.

18.

Differentiation and definition of vascular-targeted therapies.

Siemann DW, Bibby MC, Dark GG, Dicker AP, Eskens FA, Horsman MR, Marmé D, Lorusso PM.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):416-20. Review.

19.

In vitro, in vivo, and in silico analyses of the antitumor activity of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazoles.

Leong CO, Suggitt M, Swaine DJ, Bibby MC, Stevens MF, Bradshaw TD.

Mol Cancer Ther. 2004 Dec;3(12):1565-75.

20.

Secretory phospholipase A2 as a tumor-specific trigger for targeted delivery of a novel class of liposomal prodrug anticancer etherlipids.

Jensen SS, Andresen TL, Davidsen J, Høyrup P, Shnyder SD, Bibby MC, Gill JH, Jørgensen K.

Mol Cancer Ther. 2004 Nov;3(11):1451-8.

21.

Characterization of the hollow fiber assay for the determination of microtubule disruption in vivo.

Suggitt M, Swaine DJ, Pettit GR, Bibby MC.

Clin Cancer Res. 2004 Oct 1;10(19):6677-85.

22.

In-vitro cytotoxic activities of the major bromophenols of the red alga Polysiphonia lanosa and some novel synthetic isomers.

Shoeib NA, Bibby MC, Blunden G, Linley PA, Swaine DJ, Wheelhouse RT, Wright CW.

J Nat Prod. 2004 Sep;67(9):1445-9.

PMID:
15387639
23.

Temporal evaluation of methionine synthase and related metabolites in the MAC15A mouse adenocarcinoma animal model.

Blackburn A, Bibby MC, Lucock MD, Nicolaou A.

Int J Cancer. 2004 Nov 20;112(4):577-84.

24.

Phytochemistry and preliminary biological evaluation of Cyathostemma argenteum, a malaysian plant used traditionally for the treatment of breast cancer.

Khamis S, Bibby MC, Brown JE, Cooper PA, Scowen I, Wright CW.

Phytother Res. 2004 Jul;18(7):507-10.

PMID:
15305306
25.

Antitumor activity of imidazothioxanthones in murine and human tumor models in vitro and in vivo.

Varvaresou A, Iakovou K, Gikas E, Fichtner I, Fiebig HH, Kelland LR, Double JA, Bibby MC, Hendriks HR.

Anticancer Res. 2004 Mar-Apr;24(2B):907-19.

26.
27.

Vinflunine potentiates the activity of cisplatin but not 5-fluorouracil in a transplantable murine adenocarcinoma model.

Shnyder SD, Cooper PA, Gyselinck N, Hill BT, Double JA, Bibby MC.

Anticancer Res. 2003 Nov-Dec;23(6C):4815-20.

PMID:
14981930
28.

Comparative preclinical pharmacokinetic and metabolic studies of the combretastatin prodrugs combretastatin A4 phosphate and A1 phosphate.

Kirwan IG, Loadman PM, Swaine DJ, Anthoney DA, Pettit GR, Lippert JW 3rd, Shnyder SD, Cooper PA, Bibby MC.

Clin Cancer Res. 2004 Feb 15;10(4):1446-53.

29.

Comet assay and flow cytometry analysis of DNA repair in normal and cancer cells treated with known mutagens with different mechanisms of action.

Suggitt M, Fearnley J, Swaine DJ, Volpato M, Phillips RM, Bibby MC, Loadman PM, Anderson D.

Teratog Carcinog Mutagen. 2003;Suppl 2:13-29.

PMID:
14691977
30.

The role of p53 in the chemotherapeutic responses to cisplatin, doxorubicin and 5-fluorouracil treatment.

Dart DA, Picksley SM, Cooper PA, Double JA, Bibby MC.

Int J Oncol. 2004 Jan;24(1):115-25.

PMID:
14654948
31.

Combretastatin A-1 phosphate potentiates the antitumour activity of cisplatin in a murine adenocarcinoma model.

Shnyder SD, Cooper PA, Pettit GR, Lippert JW 3rd, Bibby MC.

Anticancer Res. 2003 Mar-Apr;23(2B):1619-23.

PMID:
12820431
32.

Cytochrome P450 1B1 (CYP1B1) is overexpressed in human colon adenocarcinomas relative to normal colon: implications for drug development.

Gibson P, Gill JH, Khan PA, Seargent JM, Martin SW, Batman PA, Griffith J, Bradley C, Double JA, Bibby MC, Loadman PM.

Mol Cancer Ther. 2003 Jun;2(6):527-34.

33.

An introduction to telomeres and telomerase.

Bibby MC.

Mol Biotechnol. 2003 Jul;24(3):295-301. Review.

PMID:
12777695
34.

Antitumour 2-(4-aminophenyl)benzothiazoles generate DNA adducts in sensitive tumour cells in vitro and in vivo.

Leong CO, Gaskell M, Martin EA, Heydon RT, Farmer PB, Bibby MC, Cooper PA, Double JA, Bradshaw TD, Stevens MF.

Br J Cancer. 2003 Feb 10;88(3):470-7.

35.

Anti-tumor and anti-vascular effects of the novel tubulin-binding agent combretastatin A-1 phosphate.

Holwell SE, Cooper PA, Thompson MJ, Pettit GR, Lippert LW 3rd, Martin SW, Bibby MC.

Anticancer Res. 2002 Nov-Dec;22(6C):3933-40.

PMID:
12553015
36.

Preclinical evaluation of amino acid prodrugs of novel antitumor 2-(4-amino-3-methylphenyl)benzothiazoles.

Bradshaw TD, Bibby MC, Double JA, Fichtner I, Cooper PA, Alley MC, Donohue S, Stinson SF, Tomaszewjski JE, Sausville EA, Stevens MF.

Mol Cancer Ther. 2002 Feb;1(4):239-46. Erratum in: Mol Cancer Ther. 2003 Feb;2(2):207.

37.
38.

Heterogeneity of O6-alkylguanine DNA-alkyltransferase expression in human breast tumours.

Clemons MJ, Bibby MC, El Teraifi H, Forster G, Kelly J, Banerjee S, Cadman B, Ryder WD, Howell A, Margison GP.

Br J Cancer. 2002 Jun 5;86(11):1797-802.

39.

Combretastatin A-1 phosphate a novel tubulin-binding agent with in vivo anti vascular effects in experimental tumours.

Holwell SE, Cooper PA, Grosios K, Lippert JW 3rd, Pettit GR, Shnyder SD, Bibby MC.

Anticancer Res. 2002 Mar-Apr;22(2A):707-11.

PMID:
12017147
40.

Introduction to telomeres and telomerase.

Bibby MC.

Methods Mol Biol. 2002;191:1-12. Review. No abstract available.

PMID:
11951598
41.

In vitro and in vivo activity of LS 4477 and LS 4559, novel analogues of the tubulin binder estramustine.

Nicholson KM, Phillips RM, Shnyder SD, Bibby MC.

Eur J Cancer. 2002 Jan;38(1):194-204.

PMID:
11750850
42.

A preclinical pharmacokinetic study of the bioreductive drug AQ4N.

Loadman PM, Swaine DJ, Bibby MC, Welham KJ, Patterson LH.

Drug Metab Dispos. 2001 Apr;29(4 Pt 1):422-6.

43.

Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model.

Holwell SE, Hill BT, Bibby MC.

Br J Cancer. 2001 Jan;84(2):290-5.

44.

Hollow fiber assay for tumor angiogenesis.

Phillips RM, Bibby MC.

Methods Mol Med. 2001;46:87-93. doi: 10.1385/1-59259-143-4:087.

PMID:
21340914
45.

Synthesis and antitumour activity of new derivatives of flavone-8-acetic acid (FAA). Part 4: Variation of the basic structure.

Aitken RA, Bibby MC, Cooper PA, Double JA, Laws AL, Ritchie RB, Wilson DW.

Arch Pharm (Weinheim). 2000 Jun;333(6):181-8.

PMID:
10909190
46.

High-performance liquid chromatographic analysis of AQ4N, an alkylaminoanthraquinone N-oxide.

Swaine DJ, Loadman PM, Bibby MC, Graham MA, Patterson LH.

J Chromatogr B Biomed Sci Appl. 2000 Jun 9;742(2):239-45.

PMID:
10901128
47.

Role of O6-alkylguanine-DNA alkyltransferase in the resistance of mouse spermatogenic cells to O6-alkylating agents.

Thompson MJ, Abdul-Rahman S, Baker TG, Rafferty JA, Margison GP, Bibby MC.

J Reprod Fertil. 2000 Jul;119(2):339-46.

48.

Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent.

Patterson LH, McKeown SR, Ruparelia K, Double JA, Bibby MC, Cole S, Stratford IJ.

Br J Cancer. 2000 Jun;82(12):1984-90.

49.

Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma.

Grosios K, Loadman PM, Swaine DJ, Pettit GR, Bibby MC.

Anticancer Res. 2000 Jan-Feb;20(1A):229-33.

PMID:
10769660
50.

Supplemental Content

Loading ...
Support Center